Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata

Authors: Mirmirani, Paradi | Journal Of The American Academy Of Dermatology | March 29, 2022 | PubMed abstract

Explore all publications

Back To Top